As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Integrated Biopharma Inc. The largest reported stake is DeSantis Damon's, at 41.3%. 2 filings are on record since April 17, 2026 (Schedule 13D, April 17, 2026).
Sell to companies like Integrated Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Integrated Biopharma Inc has 2 Schedule 13D or 13G filings on record since 2026-04-17. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 41.3% | 12,920,558 | SCHEDULE 13D, 2026-04-17 | 2026-04-15 | |
| 0% | 0 | SCHEDULE 13D/A, 2026-04-17 | 2026-04-15 |
Holding shares or following this stake? See who's behind Integrated Biopharma Inc and the warning signs.
Free to see. No signup.
Watch Integrated Biopharma Inc
Get an email when Integrated Biopharma Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Integrated Biopharma Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Integrated Biopharma Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Integrated Biopharma Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Desantis Carl
As a result of the death of DeSantis on August 10, 2023, all of the Group's shares of Common Stock of the Issuer were transferred to CDDS 2.0, LLC, a Florida limited liability Company, wholly owned by DeSantis's beneficiary, Damon DeSantis, on March 24, 2026, March 30, 2026 and April 15, 2026 (the "Transfer"). Following the final Transfer of shares of Common Stock, the Group ceased to be the beneficial owner of any shares of Common Stock of the Issuer. The Group, including the estate of DeSantis, has no present plans or proposals which relate to or would result in any of the matters set forth in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-04-17
DeSantis Damon
No member of the Group has a present intention or plans or proposals which relate to or could result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D. Notwithstanding anything to the contrary contained herein, each member of the Group reserves the right, depending on all relevant factors, to change their intentions with respect to any and all of the matters referred to above.Item 4 of the SCHEDULE 13D filed 2026-04-17
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-04-17 | Desantis Carl | 0% | SCHEDULE 13D/A |
| 2026-04-17 | DeSantis Damon | 41.3% | SCHEDULE 13D |
Questions about who owns Integrated Biopharma Inc
Who owns Integrated Biopharma Inc?
On this page, one holder's latest ownership filing reports 5% or more of Integrated Biopharma Inc: DeSantis Damon (41.3%, Schedule 13D, filed 2026-04-17).
When did DeSantis Damon buy into Integrated Biopharma Inc?
The filings give report dates, not purchase dates. The earliest filing from DeSantis Damon on this page is the Schedule 13D, filed 2026-04-17, reporting 41.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Integrated Biopharma Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.